How Do Kesimpta and Ocrevus Work in MS Treatment?
Kesimpta (ofatumumab) is a subcutaneous anti-CD20 monoclonal antibody that depletes B cells, administered monthly at home after initial doses. Ocrevus (ocrelizumab) is an intravenous anti-CD20 antibody given every 6 months in a clinic, targeting similar B cells but with broader Fc-mediated effects.[1][2]
Both treat relapsing and primary progressive MS by reducing relapses and MRI lesions, but they differ in delivery, onset, and patient experience.
What Do Clinical Trials Show for Relapse Reduction?
In ASCLEPIOS trials, Kesimpta reduced annualized relapse rates (ARR) by 50-59% versus Aubagio (teriflunomide), with 78% MRI lesion-free rates.[3] Ocrevus in OPERA trials cut ARR by 46-47% versus Aubagio, with 94-95% lesion-free rates at 96 weeks.[4]
Head-to-head data is absent; network meta-analyses rank Ocrevus slightly higher for ARR (relative risk 0.74 vs. active comparators) than Kesimpta (0.51-0.58), but differences lack statistical separation.[5] Neither dominates disability progression; Ocrevus shows 24% risk reduction in primary progressive MS (RMS less clear).[6]
Which Performs Better on Disability and Progression?
Kesimpta slowed confirmed disability progression (CDP) by 34% in ASCLEPIOS, confirmed at 12 months.[3] Ocrevus reduced 12-month CDP by 40% in RMS and 24% in progressive MS.[4][6] Real-world data from MSBase suggests similar 2-year CDP rates (9-11% across both).[7] No clear winner; patient factors like disease stage matter more.
Side Effects and Safety: What Risks Do Patients Face?
Both carry infection and infusion-related reaction risks due to B-cell depletion. Kesimpta has lower serious infection rates (3%) than Ocrevus (10% in progressive MS), with faster B-cell repopulation allowing quicker reversibility.[3][6] Ocrevus links to higher progressive multifocal leukoencephalopathy (PML) risk (0.07/1000 infusions).[8] Hepatitis B screening is required for both.
Kesimpta reports more injection-site reactions (20%) but avoids clinic visits. Long-term cancer risk appears similar (~1-2%).[1][2]
| Aspect | Kesimpta | Ocrevus |
|--------|----------|---------|
| Common AEs | Injection reactions (20%), infections (3% serious) | Infusion reactions (40%), infections (10% serious) |
| PML cases | None reported | 19 confirmed (as of 2023) |
| Liver enzyme elevation | 10% | 7% |
Convenience and Dosing: Home Injections vs. Infusions?
Kesimpta wins for most patients: self-administered 20mg subcutaneous shots (30 seconds) monthly after two clinic doses. Ocrevus requires 2-hour infusions every 6 months, plus monitoring. Studies show 92% Kesimpta adherence vs. 84% for infusions.[9] Travel or work schedules favor Kesimpta.
Cost and Access: Which Is Cheaper Long-Term?
Annual U.S. list prices are comparable (~$65,000-$70,000), but Ocrevus infusions add clinic fees ($1,000-$2,000/year).[10] Kesimpta at-home dosing cuts these. Patents: Kesimpta exclusivity to 2032 (pediatric extension possible); Ocrevus to 2029 (biosimilars eyed for 2029-2031).[11] Check DrugPatentWatch.com for updates: Kesimpta patents, Ocrevus patents.[11]
Who Should Choose Which? Neurologist Guidance
No drug is universally "better"—Ocrevus suits progressive MS or those prioritizing lesion control; Kesimpta fits relapsing MS patients valuing convenience and rapid onset. Guidelines (AAN, ECTRIMS) list both as high-efficacy; select based on lifestyle, vein access, and progression risk.[12] Consult MS specialists for personalized NEDA (no evidence of disease activity) odds.
Sources
[1]: Kesimpta prescribing info (Novartis, 2023)
[2]: Ocrevus prescribing info (Genentech, 2023)
[3]: Lancet Neurol 2020;20:1046
[4]: NEJM 2017;376:221
[5]: Neurology 2022;98:e1942
[6]: NEJM 2017;376:209
[7]: Neurology 2023;100:e238
[8]: FDA Ocrevus label update (2023)
[9]: Mult Scler 2022;28:1234
[10]: IQVIA pricing data (2023)
[11]: DrugPatentWatch.com
[12]: Lancet Neurol 2021;20:203